United Therapeutics Corporation (UTHR) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with record revenue, double-digit growth, and strategic product launches, which are expected to drive future growth. Management's optimism in achieving a $4 billion revenue run rate by 2027, coupled with strong product positioning in key markets, supports a positive outlook. However, there are risks related to regulatory approvals and competitive pressures. The Q&A section bolstered confidence in product developments and future growth, justifying a positive sentiment rating.
Key Financial Performance
Total Revenue (Full Year 2025) Surpassed $3 billion for the first time, representing 11% growth over full year 2024. This growth was driven by double-digit percent revenue growth from Tyvaso and Orenitram.
Total Revenue (Q4 2025) $790 million, representing 7% growth from Q4 2024. Seasonal revenue trends and timing of orders from specialty pharmaceutical distributors influenced the figures.
Tyvaso Total Revenue (Q4 2025) $464 million, a 12% increase over the previous year. This growth was underpinned by robust 24% year-over-year growth in Tyvaso DPI, reflecting strategic positioning in a growing market and increased share of voice.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Tresmi: A new proprietary drug device formulation of treprostinil in a soft mist inhaler, reducing coughing by up to 90%. Filing for approval in PAH and ILD this year, with commercial launch planned for next year.
Super prostacyclin: A once-daily pill for pulmonary hypertension, offering longer-lasting and more efficient molecule binding. Expected to address dose frequency issues.
Tyvaso for IPF: Second pivotal trial results expected next month. If confirmed, approval filing and commercial launch planned by June 2027.
Tyvaso DPI: Achieved 24% year-over-year growth, with strategic positioning in the PAH and PH-ILD markets. New 80-microgram cartridges and combination kits introduced to enhance convenience and dosing flexibility.
Revenue growth: Achieved 11% total revenue growth over 2024, surpassing $3 billion for the first time. Fourth-quarter revenue reached $790 million, a 7% increase from the previous year.
Referral rates: Highest referral rates for Tyvaso in two years, with strong momentum expected to continue.
Product differentiation: Enhancements to Tyvaso DPI platform, including low inspiratory flow requirements and consistent delivery, aim to solidify its position as the preferred inhaled prostacyclin therapy.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements involve risks and uncertainties that may cause actual results to differ materially. This includes risks related to clinical trials, product development, and regulatory approvals.
Revenue seasonality: The company experiences seasonal revenue trends, with lighter ordering in the first and fourth quarters. This variability in sales can impact short-term financial performance and may not accurately reflect patient demand or census changes.
Competitive pressures: The company faces competition in the PAH and PH-ILD markets, which could impact its market share and revenue growth. The launch of competitive products could challenge the company's positioning.
Regulatory approvals: The success of new product launches, such as Tresmi and Tyvaso for IPF, depends on obtaining timely regulatory approvals. Delays or failures in approval processes could adversely affect strategic objectives.
Supply chain and distribution: The timing and magnitude of orders from specialty pharmaceutical distributors can cause fluctuations in sales, potentially impacting revenue consistency and operational planning.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Commercial launch of Tresmi: United Therapeutics plans to file for approval of Tresmi, a soft mist inhaler for PAH and ILD, this year and commercially launch it next year. The product aims to reduce coughing by up to 90% compared to dry powder inhalers.
Once-daily super prostacyclin for PAH: The company is optimistic about the unblinding of an outcome study next week, which could lead to the launch of a once-daily super prostacyclin pill for pulmonary hypertension. This product is expected to improve dose frequency and efficiency.
Tyvaso for IPF: United Therapeutics anticipates unblinding the second pivotal trial of Tyvaso for IPF next month. If results confirm previous findings, the company plans to file for approval and commercially launch the product by June 2027.
2027 commercial launches: The company expects three transformative product launches in 2027: a once-daily super prostacyclin for PAH, the Tresmi coughless inhaler for ILD, and a new treatment for IPF that outperforms existing FDA-approved drugs.
Tyvaso DPI growth: United Therapeutics expects continued double-digit growth for Tyvaso DPI, supported by enhancements like 80-microgram cartridges and combination kits, which improve convenience and dosing flexibility.
Long-term growth expectations: The company anticipates durable double-digit growth and ongoing success over the long term, driven by its strategic positioning and product innovations.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the level of confidence in the TETON 1 study for IPF compared to TETON 2?
A:Management is extremely optimistic about the TETON 1 study, citing robust results from TETON 2 and similar baseline characteristics between the two studies. They expect the positive outcomes from TETON 2 to translate to TETON 1.
Q:What is the impact of Yutrepia on patient adds for DPI or nebulizer?
A:Management stated that Tyvaso remains the market leader for inhaled therapy in pulmonary hypertension. While there was initial curiosity about Yutrepia, healthcare providers continue to prefer Tyvaso DPI due to its ease of use and consistent delivery. Patient starts have lagged slightly due to seasonality and weather but are expected to return to sequential revenue growth by Q2.
Q:Can you provide more details about the soft mist inhaler product and its potential impact?
A:The soft mist inhaler product is expected to be easier for patients to tolerate compared to dry powder inhalers. It will be filed for approval this year and launched next year. Management withheld specific competitive advantages until FDA approval but expressed confidence in its effectiveness and patient acceptance.
Q:What is the guidance on achieving a $4 billion revenue run rate by 2027?
A:Management reaffirmed their commitment to achieving a $4 billion revenue run rate by the end of 2027, driven by double-digit revenue growth from existing products. The three new product launches are expected to further accelerate revenue growth beyond this target.
Q:What are the most important outcomes to look for in the ralinepag trial?
A:Key outcomes include statistically significant and clinically meaningful benefits in clinical worsening versus placebo, reductions in hospitalizations, and mortality. The drug's potency, long half-life, and once-a-day dosing are also expected to drive physician and patient adoption.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about the soft mist inhaler product, citing competitive reasons and pending FDA approval. Additionally, while they expressed confidence in achieving the $4 billion revenue run rate, they did not provide detailed breakdowns of contributions from the new product launches.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Annual London
Biotech Summit
Boston Leerink
CEO UT
Conference Boston
Conference Miami
Conference name
Cowen th
DPI differentiation
DPI position
DPI trajectory
Development Edgemond
Dr
Dublin affair
Healthcare Conference
Orenitram Remodulin
Tresmi
Tyvaso IPF
affair team
approval
breath
category
chat meeting
cough mist
day treatment
function
microgram
mist inhaler
news
ordering quarter
powder
rate
strength
treprostinil therapy
trial Tyvaso
unblinding
UTHR Transcript
United Therapeutics Corporation (UTHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
United Therapeutics Corporation (UTHR) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call highlights strong financial performance with record revenue, double-digit growth, and strategic product launches, which are expected to drive future growth. Management's optimism in achieving a $4 billion revenue run rate by 2027, coupled with strong product positioning in key markets, supports a positive outlook. However, there are risks related to regulatory approvals and competitive pressures. The Q&A section bolstered confidence in product developments and future growth, justifying a positive sentiment rating.
United Therapeutics Corporation (UTHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
United Therapeutics Corporation (UTHR) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-18
UTHR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
